MedTrace Logo

Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children

NCT03375775 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-04-05

No results posted yet for this study

Summary

The objective is to prospectively explore associations between immunological parameters in blood and clinical effect of subcutaneous immunotherapy (SCIT) in children with severe allergy towards pollen. Half of the children will receive SCIT while the other half will start SCIT after the study is finished. Clinical evaluations of symptoms and an immunological survey will be performed before start of SCIT and after one year of treatment. Some of the immunological parameters will also be checked after 6 months of treatment

Conditions

  • Rhinitis, Allergic
  • Conjunctivitis, Allergic
  • Asthma

Interventions

DRUG

Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy

According to standardized clinical protocol

OTHER

No immunotherapy, symptomatic treatment

These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.

Sponsors & Collaborators

Principal Investigators

  • Maria Ingemansson, MD, PHD · Karolinska Institutet

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03375775 on ClinicalTrials.gov